Recommended Free Tools
Start with ClinicalTrials.gov for international listings and India’s Clinical Trials Registry–India (CTRI) for India-specific records. Search by both therapy and condition, then confirm the live recruitment status, participating site, eligibility criteria, contact details, and record update date. A published study in India—or a registry entry marked active—does not by itself mean a site is enrolling new participants.
Where to search for optogenetic trials
Use both international and India-specific registries. A trial may appear in an international registry even when it has sites in India, so searching only one database can miss relevant records.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Optogenetics (Dahlem Workshop Reports) | $67.20 | Buy on Amazon |
As an Amazon Associate I earn from qualifying purchases.
- ClinicalTrials.gov: search international trial records and open a specific study to inspect its locations and current status.
- Clinical Trials Registry–India (CTRI): search for records relevant to studies conducted in India.
Try combinations of these terms: optogenetic, retinitis pigmentosa, blindness, MCO-010, GS030, KIO-301, and RTx-015. Searching both a therapy name and a condition can help distinguish a relevant record from a similarly named program or a study for a different disease.
Search by known trial identifier
Identifiers can take you directly to records cited in published or sponsor materials. Verify the intervention and condition in the registry rather than assuming an identifier refers to a particular therapy based on a press release or article.
#1 Best Overall
- NCT04919473: the Cuttack MCO-010 study described in a 2025 peer-reviewed report.
- NCT04945772: RESTORE.
- NCT06162585: a long-term follow-up of people previously enrolled in RESTORE.
- NCT05417126: STARLIGHT, cited in a Nanoscope announcement.
What the India study does—and does not—show
A 2025 report in Molecular Therapy describes an investigator-initiated, open-label phase I/IIa study at JPM Rotary Club of Cuttack Eye Hospital and Research Institute in Odisha. Four blind participants with retinitis pigmentosa and ABCA4 variants received one intravitreal injection of AAV2-MCO-010. The report describes improvements in visual acuity, shape discrimination, and mobility through 52 weeks. Read the peer-reviewed report for the study details.
This is a small, specific study, not proof that optogenetic treatment is an established therapy, that the result applies broadly to people with blindness, or that enrollment in Cuttack is open now. A historical study record and published results are not a current invitation to join.
How to check whether a trial is open to you
- Open the current registry record. Search the therapy or identifier on ClinicalTrials.gov and CTRI. Confirm that the record describes the treatment and condition you are interested in.
- Check recruitment status and locations. Read the overall recruitment status and the status listed for each site. A study can be active while not recruiting, or have different site statuses.
- Read the eligibility criteria. Review the inclusion and exclusion criteria, diagnosis, disease history, age requirements, and any other stated conditions. A registry listing cannot determine individual eligibility.
- Check the design and intervention. Note the phase, study design, treatment, and any equipment or procedures required. Do not assume two optogenetic programs use the same approach.
- Check the record’s update date. Recruitment and site information can change. Confirm the status in the live record rather than relying on an older article, announcement, or saved search result.
- Contact the study team listed in the current record. Ask whether the specific site is enrolling and whether the person’s diagnosis and clinical history may meet screening requirements. The study team—not the registry search—can explain screening and next steps.
What to know about India-specific trial oversight
India’s Central Drugs Standard Control Organisation (CDSCO) says its Global Clinical Trial Division handles regulatory evaluation, approval, monitoring, and oversight of global clinical trials conducted in India under the New Drugs and Clinical Trials Rules, 2019, and applicable good clinical practice guidance. Regulatory oversight is not the same as a site currently recruiting participants. For enrollment, rely on the live registry record and the study team’s confirmation.
Different programs are not interchangeable
“Optogenetic therapy” covers distinct investigational approaches. A program’s name, mechanism, equipment, disease criteria, and study status all matter when deciding whether a record is relevant.
MCO-010
The Cuttack study used AAV2-MCO-010, and Nanoscope describes MCO-010 as an optogenetic program. The published India study is evidence of a completed or historical research effort; it does not establish current enrollment at that site. See the Nanoscope site for sponsor information, and verify any trial claim against the current registry record.
GS030
GenSight describes GS030 as a modified AAV2 vector that encodes a photoactivatable channelrhodopsin for retinal ganglion cells, paired with biomimetic goggles that deliver wavelength-specific stimulation. The company says the engineered cells are less light-sensitive than normal photoreceptors, and ordinary daylight vision may not be possible without further intervention. Its clinical-development page describes PIONEER as a dose-escalation safety and tolerability study in retinitis pigmentosa. Do not confuse GS030 with GS010: GenSight separately reports that no GS010 trials are enrolling, but GS010 is not the optogenetic GS030 program.
Other pipeline names
GenSight’s 2025 Universal Registration Document discusses MCO-010, KIO-301, RTx-015, and an AGTC/Bionic Sight program. Pipeline milestones and estimates do not establish that a trial is recruiting in a particular country. Check each program’s current registry record and sponsor information before acting on a claim about availability.
The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →What the known registry records say about recruitment
ClinicalTrials.gov lists NCT06162585, the RESTORE long-term follow-up, as “Active, not recruiting”; its last posted update was March 24, 2025. It follows participants previously enrolled in RESTORE and is not a route for new candidates. Because registry status can change, check the live record before relying on that status.
The available evidence does not establish a currently recruiting Indian site for an optogenetic therapy. That is not proof that none exists: recruitment and locations are time-sensitive, so search both registries and ask the listed study team to confirm.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
